<DOC>
	<DOCNO>NCT02494297</DOCNO>
	<brief_summary>This study design compile reason specific indication prescription Cyproterone Acetate combine Ethinyl Estradiol Health Care Providers . The primary objective study characterize prescribe behavior Cyproterone Acetate combine Ethinyl Estradiol 5 European country ( Austria , Czech Republic , France , Netherlands , Spain ) , include : - prescription indication Cyproterone Acetate combine Ethinyl Estradiol - use Cyproterone Acetate combine Ethinyl Estradiol accordance update label - concomitant use Cyproterone Acetate combine Ethinyl Estradiol combine hormonal contraceptive - second line treatment Cyproterone Acetate combine Ethinyl Estradiol indication acne</brief_summary>
	<brief_title>Drug Utilization Study Prescribing Indications Cyproterone Acetate Ethinyl Estradiol 5 European Countries</brief_title>
	<detailed_description>Cyproterone acetate ( CPA ) 2mg , combination ethinyl estradiol ( EE ) 35mcg , medicinal product currently indicate treatment moderate severe acne woman reproductive age . Due combination ethinyl estradiol dosing , preparation also act effective contraceptive . In 2012 , French health authority conduct national review Cyproterone Acetate combine Ethinyl Estradiol highlight serious thromboembolic event extensive off-label use medicine contraceptive . This triggered Urgent Union Procedure begin 2013 . The European Medicines Agency 's Pharmacovigilance Risk Assessment Committee ( PRAC ) conclude benefit Cyproterone Acetate combine Ethinyl Estradiol ( cyproterone acetate 2mg / ethinyl estradiol 35mcg ) outweigh risk , provide several measure take minimize risk thromboembolism . These medicine use solely treatment moderate severe acne relate androgen sensitivity and/or hirsutism woman reproductive age . Since Cyproterone Acetate combine Ethinyl Estradiol act hormonal contraceptive , woman take medicine combination hormonal contraceptive . As one risk minimization measure , Market Authorization Holders require conduct number study include drug utilization survey . This study multi-national , cross sectional , prospective , non-interventional , drug utilization study conduct 5 country . Study participant recruit network health care professional . Physicians collect information study participant base questionnaire . This one-time survey follow-up . Bayer initiate study support unconditional grant ZEG . Bayer actively involve study conduct . Prolongation recruitment : At begin May 2016 recruitment finish 4 5 European country study conduct ( Austria , Czech Republic , The Netherlands , Spain ) . At point time , patient enrol France delay recruitment start . Therefore , agree extend recruitment phase France till January 2017 . This ensure information use Cyproterone Acetate ( combine Ethinyl Estradiol ) collect participate country .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Hirsutism</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Women prescribe Cyproterone Acetate combine Ethinyl Estradiol study period . Women willing participate drug utilization study Women willing sign inform consent Women language barrier</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>